Beijing University of Chinese Medicine, Beijing 100029, China.
Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China.
J Diabetes Res. 2020 Sep 16;2020:3634974. doi: 10.1155/2020/3634974. eCollection 2020.
Tangshen Formula (TSF) is a Chinese Medicine formula that has been reported to alleviate proteinuria and protect renal function in humans and animals with diabetic kidney disease (DKD). However, little is known about its mechanism in improving proteinuria. The dysregulation of podocyte cell-matrix adhesion has been demonstrated to play an important role in the pathogenesis and progression of proteinuric kidney diseases including DKD. In the present study, the underlying protective mechanism of TSF on podocytes was investigated using the murine model of type 2 DKD mice and advanced glycation end products (AGEs)-stimulated primary mice podocytes . Results revealed that TSF treatment could significantly mitigate reduction of podocyte numbers and foot process effacement, reduce proteinuria, and protect renal function in mice. There was a significant increase in expression of transient receptor potential canonical channel 6 (TRPC6) and a decrease in expression of talin1 in podocytes of mice. The results of AGEs-stimulated primary mice podocytes showed increased cell migration and actin-cytoskeleton rearrangement. Moreover, primary mice podocytes stimulated by AGEs displayed an increase in TRPC6-dependent Ca influx, a loss of talin1, and translocation of nuclear factor of activated T cell (NFATC) 2. These dysregulations in mice primary podocytes stimulated by AGEs could be significantly attenuated after TSF treatment. 1-Oleoyl-2-acetyl--glycerol (OAG), a TRPC6 agonist, blocked the protective role of TSF on podocyte cell-matrix adherence. In conclusion, TSF could protect podocytes from injury and reduce proteinuria in DKD, which may be mediated by the regulation of the TRPC6/Talin1 pathway in podocytes.
糖肾方(TSF)是一种中药方剂,已被报道可减轻人类和动物糖尿病肾病(DKD)患者的蛋白尿并保护肾功能。然而,其改善蛋白尿的机制知之甚少。已证实,足细胞-细胞外基质黏附的失调在蛋白尿性肾脏疾病(包括 DKD)的发病机制和进展中发挥重要作用。在本研究中,使用 2 型 DKD 小鼠模型 和 AGEs 刺激的原代小鼠足细胞 研究了 TSF 对足细胞的潜在保护机制。结果表明,TSF 治疗可显著减轻 小鼠足细胞数量减少和足突融合,减少蛋白尿,并保护肾功能。TRPC6 的表达显著增加,而足细胞中 talin1 的表达减少。AGEs 刺激的原代小鼠足细胞的结果显示细胞迁移和肌动蛋白细胞骨架重排增加。此外,AGEs 刺激的原代小鼠足细胞显示出依赖于 TRPC6 的 Ca2+内流增加、talin1 丢失和活化 T 细胞核因子(NFATC)2 易位。AGEs 刺激的原代小鼠足细胞中的这些失调在 TSF 治疗后可显著减轻。TRPC6 激动剂 1-油酰基-2-乙酰基-sn-甘油(OAG)阻断了 TSF 对足细胞细胞-基质黏附的保护作用。总之,TSF 可保护足细胞免受损伤并减少 DKD 中的蛋白尿,这可能是通过调节足细胞中的 TRPC6/Talin1 通路介导的。